A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

• Main Authors: Mariane Teodoro Fernandes (Author), Jacob J Adashek (Author), Carmelia Maria Noia Barreto (Author), Ana Cláudia Barbin Spinosa (Author), Barbara de Souza Gutierres (Author), Gilberto Lopes (Author), Auro del Giglio (Author), Pedro Nazareth Aguiar Jr (Author)
• Format: Book
• Published: BioExcel Publishing Ltd, 2018-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors...